Open access · CC-BY
via OpenAlex
Nicotinamide Riboside and CD38: Covalent Inhibition and Live-Cell Labeling
Guoyun Kao, Xiaonan Zhang, Fariborz Nasertorabi, Benjamin B. Katz, Zeyang Li, Zhefu Dai, Zeyu Zhang, Lei Zhang, Stan G. Louie, Vadim Cherezov, Yong Zhang
JACS Au · 2024 · ▲ 9 citations
Abstract
High Resolution Image Download MS PowerPoint Slide Nicotinamide adenine dinucleotide (NAD + ) is required for a myriad of metabolic, signaling, and post-translational events in cells. Its levels in tissues and organs are closely associated with health conditions. The homeostasis of NAD + is regulated by biosynthetic pathways and consuming enzymes. As a membrane-bound protein with robust NAD + hydrolase activity, cluster of differentiation 38 (CD38) is a major degrader of NAD + . Deficiency or inhibition of CD38 enhances NAD + levels in vivo, resulting in various therapeutic benefits. As a metabolic precursor of NAD +, nicotinamide mononucleotide can be rapidly hydrolyzed by CD38, whereas nicotinamide riboside (NR) lacks CD38 substrate activity. Given their structural similarities, we explored the inhibition potential of NR. To our surprise, NR exhibits marked inhibitory activity against CD38 by forming a stable ribosyl–ester bond with the glutamate residue 226 at the active site. Inspired by this discovery, we designed and synthesized a clickable NR featuring an azido substitution at the 5′-OH position. This cell-permeable NR analogue enables covalent labeling and imaging of both extracellular and intracellular CD38 in live cells. Our work discovers an unrecognized molecular function of NR and generates a covalent probe for health-related CD38. These findings offer new insights into the role of NR in modulating NAD + metabolism and CD38-mediated signaling as well as an innovative tool for in-depth studies of CD38 in physiology and pathophysiology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1021/jacsau.4c00695
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Kao, G., Zhang, X., Nasertorabi, F., Katz, B.B., Li, Z., Dai, Z., Zhang, Z., Zhang, L., Louie, S.G., Cherezov, V., & Zhang, Y. (2024). Nicotinamide Riboside and CD38: Covalent Inhibition and Live-Cell Labeling. <em>JACS Au</em>. https://doi.org/10.1021/jacsau.4c00695
Vancouver
Kao G, Zhang X, Nasertorabi F, Katz BB, Li Z, Dai Z, et al. Nicotinamide Riboside and CD38: Covalent Inhibition and Live-Cell Labeling. JACS Au. 2024. doi:10.1021/jacsau.4c00695.
BibTeX
@article{guoyun2024Nicoti,
title = {Nicotinamide Riboside and CD38: Covalent Inhibition and Live-Cell Labeling},
author = {Guoyun Kao and Xiaonan Zhang and Fariborz Nasertorabi and Benjamin B. Katz and Zeyang Li and Zhefu Dai and Zeyu Zhang and Lei Zhang and Stan G. Louie and Vadim Cherezov and Yong Zhang},
journal = {JACS Au},
year = {2024},
doi = {10.1021/jacsau.4c00695},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Medicine 2021
Open access · CC-BY
NAD+ Homeostasis in Diabetic Kidney Disease
Frontiers in sports and active living 2026
Open access · OA
The role of exercise in modulating NAD+ metabolic enzymes: mechanisms and health benefits.
Nutrients 2026
Open access · OA
NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities.
Frontiers in Aging Neuroscience 2020
Open access · CC-BY
Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease
Nutrients 2024
Open access · CC-BY
Effect of Nicotinamide Riboside Against the Exhaustion of CD8+ T Cells via Alleviating Mitochondrial Dysfunction
American Journal of Physiology-Heart and Circulatory Physiology 2017
Open access · OA